Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jennifer A Piesvaux

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
ACS Medicinal Chemistry Letters|March 19, 2021
Identification of Potent Reverse Indazole Inhibitors for HPK1Elsie C Yu, Joey L Methot, Xavier Fradera, et al.
Bioorganic & Medicinal Chemistry Letters|April 20, 2010
Macrocyclic BACE inhibitors: Optimization of a micromolar hit to nanomolar leadsYifang Huang, Eric D Strobel, Chih Y Ho, et al.
ACS Medicinal Chemistry Letters|April 16, 2021
Discovery of Diaminopyrimidine Carboxamide HPK1 Inhibitors as Preclinical Immunotherapy Tool CompoundsBrandon A Vara, Samuel M Levi, Abdelghani Achab, et al.
Journal of Medicinal Chemistry|March 25, 2022
Discovery of MK-1454: A Potent Cyclic Dinucleotide Stimulator of Interferon Genes Agonist for the Treatment of CancerWonsuk Chang, Michael D Altman, Charles A Lesburg, et al.
Science (New York, N.Y.)|August 22, 2020
An orally available non-nucleotide STING agonist with antitumor activityBo-Sheng Pan, Samanthi A Perera, Jennifer A Piesvaux, et al.
ACS Medicinal Chemistry Letters|July 14, 2026
Discovery of MK-2118, a Small-Molecule Agonist of STINGTimothy Henderson, Michael D Altman, Alexei V Buevich, et al.
Journal of Medicinal Chemistry|December 8, 2022
Discovery and Optimization of Potent, Selective, and Brain-Penetrant 1-Heteroaryl-1<i>H</i>-Indazole LRRK2 Kinase Inhibitors for the Treatment of Parkinson's DiseaseDavid A Candito, Vladimir Simov, Anmol Gulati, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
ACS Medicinal Chemistry Letters|March 19, 2021
Identification of Potent Reverse Indazole Inhibitors for HPK1Elsie C Yu, Joey L Methot, Xavier Fradera, et al.
Bioorganic & Medicinal Chemistry Letters|April 20, 2010
Macrocyclic BACE inhibitors: Optimization of a micromolar hit to nanomolar leadsYifang Huang, Eric D Strobel, Chih Y Ho, et al.
ACS Medicinal Chemistry Letters|April 16, 2021
Discovery of Diaminopyrimidine Carboxamide HPK1 Inhibitors as Preclinical Immunotherapy Tool CompoundsBrandon A Vara, Samuel M Levi, Abdelghani Achab, et al.
Journal of Medicinal Chemistry|March 25, 2022
Discovery of MK-1454: A Potent Cyclic Dinucleotide Stimulator of Interferon Genes Agonist for the Treatment of CancerWonsuk Chang, Michael D Altman, Charles A Lesburg, et al.
Science (New York, N.Y.)|August 22, 2020
An orally available non-nucleotide STING agonist with antitumor activityBo-Sheng Pan, Samanthi A Perera, Jennifer A Piesvaux, et al.
ACS Medicinal Chemistry Letters|July 14, 2026
Discovery of MK-2118, a Small-Molecule Agonist of STINGTimothy Henderson, Michael D Altman, Alexei V Buevich, et al.
Journal of Medicinal Chemistry|December 8, 2022
Discovery and Optimization of Potent, Selective, and Brain-Penetrant 1-Heteroaryl-1<i>H</i>-Indazole LRRK2 Kinase Inhibitors for the Treatment of Parkinson's DiseaseDavid A Candito, Vladimir Simov, Anmol Gulati, et al.
Pageof 1